[A26-27] Inebilizumab (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V
Last updated 15.06.2026
Project no.:
A26-27
Commission:
Commission awarded on 12.03.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Indication:
Adults with generalized myasthenia gravis for whom add-on therapy to standard treatment is an option
Result of dossier assessment:
- Patients with anti-AChR antibody-positive generalized myasthenia gravis: added benefit not proven
- Patients with anti-MuSK antibody-positive generalized myasthenia gravis: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A26-27
| Project no. | Title | Status |
|---|---|---|
| A22-74 | Inebilizumab (neuromyelitis optica spectrum disorders [NMOSD]) – Benefit assessment according to § 35a SGB V | Commission completed |
| A26-26 | Inebilizumab (immunoglobulin G4-related disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |